FDA Approves Injectable At-Home Version of Eisai-Biogen Alzheimer's Drug Leqembi

Spread the Message

Read Time:4 Minute, 10 Second

On August 29, 2025, the U.S. Food and Drug Administration (FDA) approved an injectable subcutaneous formulation of the Alzheimer’s disease drug Leqembi, developed by Eisai and Biogen. This marks a significant advancement, making Leqembi the first Alzheimer’s treatment that can be self-administered at home as a weekly under-the-skin injection, following an initial 18-month course of intravenous (IV) infusions. The new injectable version, branded as Leqembi IQLIK, is set to be available to patients by October 6, 2025, with an annual list price of $19,500.

Key Findings and Developments

Leqembi was initially approved by the FDA in 2023 as an intravenous infusion treatment designed to slow Alzheimer’s disease progression in patients with mild cognitive impairment or early-stage dementia. The drug targets the underlying cause of Alzheimer’s by reducing amyloid beta plaques, toxic sticky protein deposits in the brain associated with the disease. Until now, patients had to receive bi-weekly infusions in a clinical setting, which posed logistical and access challenges.

The newly approved Leqembi IQLIK formulation offers a maintenance dosing option after completing 18 months of bi-weekly IV infusions. Patients can either continue with monthly IV infusions or switch to the once-weekly subcutaneous injection at home, which requires about a minute to administer. This change significantly reduces treatment burden and could broaden patient access by eliminating the need for frequent, lengthy clinical visits.

Expert Commentary and Context

Lynn Kramer, Chief Clinical Officer at Eisai, told Reuters that the at-home injectable option “may open more infusion chairs for even greater initiation of the therapy for patients,” highlighting the potential for increased treatment uptake and accessibility. This ease of administration could particularly benefit elderly patients and caregivers by simplifying treatment logistics.

Biogen has been working to improve the uptake of Leqembi, which initially faced hurdles due to:

Modest cognitive benefits shown in clinical trials,
High treatment costs,
The inconvenience of bi-monthly IV infusions,
And the necessity for frequent brain imaging to monitor for side effects.

This injectable version aims to address these challenges by making the maintenance phase more patient-friendly, hoping to encourage more widespread use among eligible Alzheimer’s patients.

Public Health Implications

Alzheimer’s disease remains a major public health challenge without many effective therapies that alter disease progression. Treatments like Leqembi that target amyloid beta pathology represent a new wave of disease-modifying options, potentially slowing cognitive decline in the early stages. The availability of an at-home injectable treatment could improve patient adherence and quality of life by reducing hospital visits and enabling more flexible management.

However, the therapy is intended only for patients at the mild cognitive impairment or mild dementia stage, emphasizing the importance of early diagnosis and specialist consultation for treatment eligibility.

Safety Considerations and Monitoring

Despite its benefits, Leqembi requires careful monitoring due to potential side effects involving brain swelling and bleeding, known as amyloid-related imaging abnormalities (ARIA). In August 2025, the FDA recommended earlier and more frequent MRI scans to detect ARIA before serious complications develop, reflecting ongoing efforts to optimize safety protocols for patients on this drug.

Healthcare providers must balance the modest cognitive improvements observed with the risks and costs of treatment, underscoring the necessity for individualized decision-making based on patient-specific factors.

Limitations and Counterpoints

While the injectable version offers convenience, several limitations remain:

The cognitive benefits of Leqembi, although statistically significant, are modest and may not result in noticeable improvements for all patients.
The high cost ($19,500 annually for the injectable maintenance dose) may limit access for some patients, even with insurance.
The need for regular MRI scans to monitor for brain side effects remains a logistical and financial burden.
Some experts underscore the need for further studies to assess long-term outcomes and real-world effectiveness of the injectable formulation.

These factors emphasize the importance of shared decision-making between patients, families, and healthcare providers.

Practical Takeaways for Patients and Caregivers

Patients currently on Leqembi IV infusion may soon have an option to switch to a weekly, at-home injection for maintenance treatment, improving convenience.
Early diagnosis of Alzheimer’s disease, especially in mild cognitive impairment stages, is crucial to benefit from such disease-modifying therapies.
Close monitoring via brain imaging is essential to mitigate treatment risks.
Patients and caregivers should discuss with neurologists or specialized healthcare teams about the risks, benefits, and logistics of starting or continuing Leqembi treatment.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.